fda warning letters glp-1 compounding september 2025 8, 2025: launches an import alert listing safe manufacturers – Partnership for Safe Medicines CDER Warning Letters Jump 50%

Sequoias report shows 19% of companies are currently implementing this requirement, with an additional 5% adopting it for the first time this year

Legal and Regulatory Framework Governing Compounded GLP-1 Medications Federal Compounding Regulations: Compounding pharmacies operate under federal and state regulations that permit creation of customized medication formulations when: A licensed healthcare provider prescribes the compounded medication for a specific patient based on medical need The compounded medication is not essentially a copy of a commercially available FDA-approved product (exception: during FDA-documented drug shortages) The compounding is done by a state-licensed pharmacy or FDA-registered outsourcing facility Active pharmaceutical ingredients are sourced from FDA-registered facilities (though FDA registration does not indicate FDA approval or quality verification) FDA Drug Shortage Impact on Compounded Medication Availability: During periods when FDA designates semaglutide or tirzepatide as being in shortage, compounding pharmacies have expanded legal authority to prepare compounded versions of these medications

Many require hoops like prior authorization or exclude weight loss coverage outright

Others focus on payout speed and helpfulness of support staff

16.0 mg/dL, respectively

Supports Long-Term Weight Management: Contributes to a reduction in Body Mass Index (BMI)